A detailed history of Two Sigma Investments, LP transactions in Oric Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 184,075 shares of ORIC stock, worth $1.56 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
184,075
Previous 262,514 29.88%
Holding current value
$1.56 Million
Previous $1.86 Million 1.67%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$7.52 - $11.9 $589,861 - $933,424
-78,439 Reduced 29.88%
184,075 $1.89 Million
Q2 2024

Aug 14, 2024

BUY
$6.63 - $12.93 $1.02 Million - $1.98 Million
153,505 Added 140.82%
262,514 $1.86 Million
Q1 2024

May 15, 2024

BUY
$8.04 - $16.03 $32,151 - $64,103
3,999 Added 3.81%
109,009 $1.5 Million
Q4 2023

Feb 14, 2024

BUY
$5.41 - $9.43 $399,777 - $696,839
73,896 Added 237.5%
105,010 $966,000
Q3 2023

Nov 14, 2023

SELL
$6.05 - $9.28 $456,781 - $700,649
-75,501 Reduced 70.82%
31,114 $188,000
Q2 2023

Aug 14, 2023

BUY
$4.95 - $8.4 $312,815 - $530,838
63,195 Added 145.54%
106,615 $827,000
Q1 2023

May 15, 2023

SELL
$4.26 - $6.75 $13,414 - $21,255
-3,149 Reduced 6.76%
43,420 $247,000
Q4 2022

Feb 14, 2023

SELL
$2.41 - $5.89 $307,265 - $750,951
-127,496 Reduced 73.25%
46,569 $274,000
Q3 2022

Nov 14, 2022

SELL
$3.15 - $5.24 $193,003 - $321,060
-61,271 Reduced 26.04%
174,065 $557,000
Q2 2022

Aug 15, 2022

SELL
$2.7 - $7.07 $226,851 - $594,014
-84,019 Reduced 26.31%
235,336 $1.05 Million
Q1 2022

May 16, 2022

BUY
$4.54 - $16.1 $1.45 Million - $5.14 Million
319,355 New
319,355 $1.71 Million
Q3 2021

Nov 15, 2021

SELL
$15.9 - $25.22 $487,191 - $772,766
-30,641 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$17.37 - $25.34 $532,234 - $776,442
30,641 New
30,641 $542,000

Others Institutions Holding ORIC

About Oric Pharmaceuticals, Inc.


  • Ticker ORIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,576,700
  • Market Cap $336M
  • Description
  • ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...
More about ORIC
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.